Phase I/II Study of R340 (Capecitabine), L-OHP (Oxaliplatin) and R435 (Bevacizumab) in Advanced and/or Metastatic Colorectal Cancer
This study will evaluate the efficacy, safety and pharmacokinetics of Capecitabine (2000
mg/m2/day po, day 1 pm-day 15 am q3w), Oxaliplatin (130 mg/m2 iv, day 1 q3w) and Bevacizumab
(7.5 mg/kg iv, day 1 q3w) in patients with advanced and/or metastatic colorectal cancer.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate: Response Evaluation Criteria in Solid Tumors (RECIST)
Clinical Development Department 3, Group 6
Japan: Ministry of Health, Labor and Welfare